Literature DB >> 9148008

Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.

F Oberti1, H Rifflet, M Y Maïga, C Pilette, Y Gallois, O Douay, J J Le Jeune, J L Saumet, P Calès.   

Abstract

BACKGROUND/AIMS: It has been suggested that the early administration of propranolol (PR) and a low sodium diet may prevent the development of portosystemic shunts in animals with presinusoidal portal hypertension. Our aim was to study the hemodynamic effects of the early and chronic administration of PR and spironolactone (SPN), alone or in combination, in a model of hepatic fibrosis and sinusoidal portal hypertension induced in rats by bile duct ligation.
METHODS: A blind study was performed in 40 Sprague-Dawley rats divided into four groups: placebo (PL), PR (75 mg/kg per day), SPN (100 mg/kg per day), and PR+SPN at the same doses. Drugs were administered by daily gavage over a 4-week period as soon as bile duct ligation was performed. At day 28, the splanchnic and systemic hemodynamics (radiolabeled microspheres) were evaluated.
RESULTS: a) Systemic hemodynamics: PR significantly reduced cardiac index and increased vascular resistance, SPN had no significant effect and PR+SPN significantly decreased mean arterial pressure. b) Splanchnic hemodynamics: portal venous pressure (PL: 15.5 +/- 1.5, PR: 14.8 +/- 1.0, SPN: 13.5 +/- 2.1, PR+SPN: 15.0 +/- 1.3 mmHg, p < 0.05) and portosystemic shunts (PL: 30 +/- 31, PR: 13 +/- 14, SPN: 5 +/- 4, PR+SPN: 29 +/- 33%, p < 0.05) were significantly reduced in the SPN group; other hemodynamic parameters were not significantly altered. In multivariate analysis, the only determinant of portosystemic shunts was portal pressure but with a low R2 (0.2).
CONCLUSIONS: In this model, the early administration of PR, alone or in combination with SPN, had no beneficial hemodynamic effects. On the other hand, SPN alone decreased portal pressure and prevented portosystemic shunts. Therefore, this drug may have beneficial effects in patients with early portal hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148008     DOI: 10.1016/s0168-8278(97)80023-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

1.  Pharmacological effects are model specific in animal models of portal hypertension.

Authors:  Flemming Bendtsen; Søren Møller
Journal:  Hepatol Int       Date:  2008-09-03       Impact factor: 6.047

2.  Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.

Authors:  Lionel Fizanne; Nicolas Régenet; Jianhua Wang; Frédéric Oberti; Frédéric Moal; Jerôme Roux; Yves Gallois; Sophie Michalak; Paul Calès
Journal:  Hepatol Int       Date:  2008-04-12       Impact factor: 6.047

Review 3.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.